Illumina Announces Winners of MiSeq® Grant Program
Illumina, Inc. (NASDAQ: ILMN) today announced the winners of its MiSeq grant program at the American Society of Human Genetics (ASHG) annual meeting in San Francisco. Illumina received almost 850 applications from researchers in over 40 countries in fields as diverse as microbiology, cancer, inherited disease, and evolutionary biology.
The awardees are:
- Ramunas Stepanauskas, from the Bigelow Laboratory for Ocean Sciences, East Boothbay, Maine, for sequencing single cells from unculturable strains of bacteria in the dark ocean;
- Stephen Doyle, from La Trobe University, Melbourne, Australia, for investigating drug resistance in the causative agent of African river blindness; and
- Karin Haack, from the Texas Biomedical Research Institute, San Antonio, Texas, for targeted resequencing of genes implicated in cardiovascular disease.
“We are excited to broaden access to MiSeq and engage with researchers who are developing novel applications with Illumina technology,” said Gary Schroth, Distinguished Scientist at Illumina. “The grant applications we received showed an incredible range of creativity. We look forward to working with the grant recipients as they make discoveries, innovate, and accelerate the research being done in their areas of expertise.”
The MiSeq grant program was developed to enable any researcher – from novices to current Illumina customers anywhere in the world – to gain access to next generation sequencing (NGS) to further their research, as well as to advance innovation in applications that can only be enabled by NGS capabilities.
Entries were judged by a team of scientific reviewers from Illumina and evaluated based upon scientific merit, originality, and applicability to the unique capabilities of the MiSeq system. Each of the three winners will receive a MiSeq, sample preparation and sequencing reagent kits, data analysis software and storage, training, and technical support valued at more than $150,000 per prize.
For more information, please visit: www.illumina.com/miseqgrant.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.